Kauffman Kevin J, Oberli Matthias A, Dorkin J Robert, Hurtado Juan E, Kaczmarek James C, Bhadani Shivani, Wyckoff Jeff, Langer Robert, Jaklenec Ana, Anderson Daniel G
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Mol Ther Nucleic Acids. 2018 Mar 2;10:55-63. doi: 10.1016/j.omtn.2017.11.005. Epub 2017 Nov 21.
mRNA therapeutics hold promise for the treatment of diseases requiring intracellular protein expression and for use in genome editing systems, but mRNA must transfect the desired tissue and cell type to be efficacious. Nanoparticle vectors that deliver the mRNA are often evaluated using mRNA encoding for reporter genes such as firefly luciferase (FLuc); however, single-cell resolution of mRNA expression cannot generally be achieved with FLuc, and, thus, the transfected cell populations cannot be determined without additional steps or experiments. To more rapidly identify which types of cells an mRNA formulation transfects in vivo, we describe a Cre recombinase (Cre)-based system that permanently expresses fluorescent tdTomato protein in transfected cells of genetically modified mice. Following in vivo application of vectored Cre mRNA, it is possible to visualize successfully transfected cells via Cre-mediated tdTomato expression in bulk tissues and with single-cell resolution. Using this system, we identify previously unknown transfected cell types of an existing mRNA delivery vehicle in vivo and also develop a new mRNA formulation capable of transfecting lung endothelial cells. Importantly, the same formulations with mRNA encoding for fluorescent protein delivered to wild-type mice did not produce sufficient signal for any visualization in vivo, demonstrating the significantly improved sensitivity of our Cre-based system. We believe that the system described here may facilitate the identification and characterization of mRNA delivery vectors to new tissues and cell types.
信使核糖核酸(mRNA)疗法有望用于治疗需要细胞内蛋白质表达的疾病以及用于基因组编辑系统,但mRNA必须转染所需的组织和细胞类型才能有效。递送mRNA的纳米颗粒载体通常使用编码报告基因(如萤火虫荧光素酶(FLuc))的mRNA进行评估;然而,使用FLuc通常无法实现mRNA表达的单细胞分辨率,因此,在没有额外步骤或实验的情况下无法确定转染的细胞群体。为了更快速地确定mRNA制剂在体内转染哪些类型的细胞,我们描述了一种基于Cre重组酶(Cre)的系统,该系统在基因改造小鼠的转染细胞中永久表达荧光tdTomato蛋白。在体内应用携带Cre的mRNA后,可以通过Cre介导的tdTomato在大块组织中的表达以及单细胞分辨率来可视化成功转染的细胞。使用该系统,我们在体内鉴定了现有mRNA递送载体以前未知的转染细胞类型,还开发了一种能够转染肺内皮细胞的新型mRNA制剂。重要的是,将编码荧光蛋白的mRNA的相同制剂递送至野生型小鼠时,未产生足够的信号用于体内任何可视化,这表明我们基于Cre的系统具有显著提高的灵敏度。我们相信,本文所述的系统可能有助于鉴定和表征mRNA递送载体在新组织和细胞类型中的情况。